Zydus settles patent case over Aptalis drug Canasa
New Delhi: Zydus group firm Cadila Healthcare on Monday said patent litigation relating to Aptalis' drug Canasa used for treatment of ulcerative colitis has been settled.
As a result of the settlement, the company's "US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Canasa in the United States beginning on June 13, 2019, or earlier under certain circumstances," Cadila Healthcare said in a statement.
Zydus Cadila had earlier received tentative approval from the United States Food and Drug Administration (USFDA) to market its generic version of Canasa (mesalamine suppository 1 g), it added.
Canasa is indicated to treat mildly to moderately active ulcerative colitis.
The company's product will be produced at the group's topical plant at Ahmedabad, Cadila Healthcare said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd